A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VEN / venlafaxine

[Related PubMed/MEDLINE]
Total Number of Papers: 107
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VEN  (>> Co-occurring Abbreviation)
Long Form:   venlafaxine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Degradation of pharmaceutical mixtures in aqueous solutions using UV/peracetic acid process: Kinetics, degradation pathways and comparison with UV/H2O2. CBZ, FLU, SFX
2020 Effect of UV dose on degradation of venlafaxine using UV/H2O2: perspective of augmenting UV units in wastewater treatment. WWTPs
2020 Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population. ODV, TDM
2020 Influence of Zuojin Pill on the Metabolism of Venlafaxine in Vitro and in Rats and Associated Herb-Drug Interaction. HLM, ODV, rhP450s, RLM, ZJP
2020 Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. AUC, CI, P-gp
2020 Pre-pubertal, low-intensity exercise does not require concomitant venlafaxine to induce robust, late-life antidepressant effects in Flinders sensitive line rats. EXE, FSL, MDD, NA, PND35
2020 Pregnancy exposure to venlafaxine-Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. ODV
2020 Recent Advances in the Electrochemical Sensing of Venlafaxine: An Antidepressant Drug and Environmental Contaminant. ---
2020 Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure. FLX, MRM, NFLX, ODV, VTX
10  2019 Ancestral Fluoxetine Exposure Sensitizes Zebrafish to Venlafaxine-Induced Reductions in Cortisol and Spawning. FLX
11  2019 Antidepressant mechanisms of venlafaxine involving increasing histone acetylation and modulating tyrosine hydroxylase and tryptophan hydroxylase expression in hippocampus of depressive rats. CUS, TH, TPH
12  2019 CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population. MDD
13  2019 Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. ODV
14  2019 Hidden in the sand: Alteration of burying behaviour in shore crabs and cuttlefish by antidepressant exposure. FLX
15  2019 Imipramine and Venlafaxine Differentially Affect Primary Glial Cultures of Prenatally Stressed Rats. IMI, LPS
16  2019 Pharmacokinetic correlates of venlafaxine: associated adverse reactions. ADR, ODVEN, UKU
17  2019 Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. CGI-I, MWU, ODVEN
18  2019 Role of venlafaxine in relapse to methamphetamine seeking. Potential treatment option for drug dependence. ANOVA, CPP, METH
19  2019 Venlafaxine pharmacogenetics:a comprehensive review. ---
20  2019 Venlafaxine plus melatonin ameliorate reserpine-induced depression-like behavior in zebrafish. DA, DAT, ELISA, mao, MT, NA, NET, VMAT2
21  2018 Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. ODVEN
22  2018 Dispersive liquid-liquid microextraction for the quantification of venlafaxine in environmental waters. WWTP
23  2018 How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. AMLO, ODVEN, RAMI
24  2018 Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. ---
25  2018 Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression? ESC, NOR, SD, UPPS
26  2018 Reduced clearance of venlafaxine in a combined treatment with quetiapine. ODVEN
27  2018 Sex and body weight are major determinants of venlafaxine pharmacokinetics. ODVEN
28  2018 Synthetic hospital wastewater treatment by coupling submerged membrane bioreactor and electrochemical advanced oxidation process: Kinetic study and toxicity assessment. CBZ, EO, IBU, MBR
29  2018 The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats. BUP, LTM, OF, PAR, STM
30  2018 The influence of aripiprazole and venlafaxine on the antidepressant-like effect observed in prenatally stressed rats (animal model of depression). ARI, FST
31  2018 Toxicity assessment of five emerging pollutants, alone and in binary or ternary mixtures, towards three aquatic organisms. CBZ, EPs, MP, TCS
32  2018 Toxicological Assessment of Venlafaxine: Acute and Subchronic Toxicity Study in Rats. ---
33  2018 Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin-norepinephrine reuptake inhibitor drugs. ATO, DUL, LODs, UAMDSPME
34  2018 Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. LLE, MTBE
35  2017 Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer. ODV
36  2017 Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? ---
37  2016 Pharmaceuticals and personal care products (PPCPs) in Australia's largest inland sewage treatment plant, and its contribution to a major Australian river during high and low flow. ATL, CBZ, CHP, DPH, FLX, MET, PPCPs, PRL, SER, SOT, TCS
38  2016 Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. NDV, NODV, ODV
39  2016 Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry. CV, MIP, MISPE, NDV, NIP, ODV
40  2015 Assessment of in-utero venlafaxine induced, ROS-mediated, apoptotic neurodegeneration in fetal neocortex and neurobehavioral sequelae in rat offspring. ROS
41  2015 Clinical drug-drug interactions: focus on venlafaxine. SSRIs
42  2015 Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. DDV, NDV, ODV, PMs
43  2015 Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro. ---
44  2015 Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. ODVEN
45  2014 Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS. DBS, ODV, TDM
46  2014 Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue. ODV
47  2014 First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma. ODV
48  2014 Occurrence of venlafaxine residues and its metabolites in marine mussels at trace levels: development of analytical method and a monitoring program. NDV, NODDV, PAHs, PCBs, QuEChERS
49  2014 Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. ODV
50  2014 The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis. ODV
51  2014 Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. ---
52  2013 A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. ODV, PM
53  2013 An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. AUC, BP, CIs, ECG, GMRs, LDX, ODV, TEAEs, VXR
54  2013 Chronic, low concentration exposure to pharmaceuticals impacts multiple organ systems in zebrafish. ACE, CBZ, GEM
55  2013 Degradation of lidocaine, tramadol, venlafaxine and the metabolites O-desmethyltramadol and O-desmethylvenlafaxine in surface waters. LDC, ODT, ODV, TRA
56  2013 High impact child abuse may predict risk of elevated suicidality during antidepressant initiation. ESC, MDD, RFLS
57  2013 High-throughput method for the analysis of venlafaxine in pharmaceutical formulations and biological fluids, using a tris(2,2'-bipyridyl) ruthenium(II)-peroxydisulphate chemiluminescence system in a two-chip device. CL, RSD
58  2013 Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma. ODV
59  2013 Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. ESC, HDRS
60  2013 Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. ECT, Li, NT
61  2013 Psychomotor depressive symptoms may differentially respond to venlafaxine. ESC, MDD, NET
62  2013 Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. ESI, MRM, ODV
63  2013 [Extraction techniques for analysis of venlafaxine and its metabolites in biological matrices]. ---
64  2012 ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. ESC, MDD, SNPs
65  2012 Concomitant use of tramadol and venlafaxine - evaluation of antidepressant-like activity and other behavioral effects in rats. CMC, i.p, TRM
66  2012 Distribution of antidepressant residues in wastewater and biosolids following different treatment processes by municipal wastewater treatment plants in Canada. CBZ, CIT, DVEN, STPs
67  2012 Impact of wastewater treatment plant discharge of lidocaine, tramadol, venlafaxine and their metabolites on the quality of surface waters and groundwater. LDC, ODT, ODV, TRA, WWTP
68  2012 Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. DDV, NDV, ODV
69  2012 Occurrence and removal of lidocaine, tramadol, venlafaxine, and their metabolites in German wastewater treatment plants. LDC, MEGX, ODT, ODV, TRA, WWTPs
70  2012 Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system. ABS, ADI, ODV
71  2012 The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. ODVEN
72  2012 Venlafaxine and atenolol disrupt epinephrine-stimulated glucose production in rainbow trout hepatocytes. ATEN, GLUT2
73  2012 Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear. GAD, MD, PTSD
74  2011 Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. N-VEN, OVEN, SSRIs
75  2011 Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. BL, ECT, HRQoL, Li, NT, RUL, SF-36
76  2011 No influence of body weight on serum levels of antidepressants. AMI, CLO, DOX, ESC
77  2011 Selective uptake and biological consequences of environmentally relevant antidepressant pharmaceutical exposures on male fathead minnows. BUP, FLX, SER
78  2011 Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. ODV
79  2010 Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences. CIT, ESC, MD
80  2010 Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine. EM, ODV, PK, PM, UM
81  2010 Effect of venlafaxine and nicotine on the level of neurotransmitters and their metabolites in rat brains. DA, NA, NIC
82  2010 Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis. FLX, MDD
83  2010 Neonatal hair analysis by liquid chromatography-high-resolution mass spectrometry to reveal gestational exposure to venlafaxine. ---
84  2010 Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ESI, LLOQ, MRM, ODV
85  2009 Dose-finding study of fluoxetine and venlafaxine for the treatment of self-injurious and stereotypic behavior in rhesus macaques (Macaca mulatta). CSF 5HIAA, FLX
86  2009 Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). BDNF, NIC, OLA
87  2009 Invivo antioxidant status: a putative target of antidepressant action. CAT, FLU, GR, GST, IMI, MDA, SOD
88  2009 Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. CBT
89  2009 Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. ARI, ATO, CLO, DARI, DSTN, DUL, NCLO, OLA, OVEN, STN
90  2008 Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study. IS, MRM, ODV
91  2007 High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. DDV, ESI, NDV, ODV, SIR, TDM
92  2007 Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column. ESI, ODV, SIR
93  2006 CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. ODV, WT
94  2006 The influence of tobacco smoke and nicotine on antidepressant and memory-improving effects of venlafaxine. NIC
95  2005 Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma. ESC, LC-MS-MS, ODV, SPE
96  2004 Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. ---
97  2004 High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. ODV
98  2003 Comparison of behavioural effects of venlafaxine and imipramine in rats. IMI, IT
99  2002 Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy. HE, PCS
100  2002 Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. DDV, NDV, ODV, TDM